REG - Avacta Group PLC - Block Listing Six Monthly Return

AvactaAnnouncement

28/10/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241028:nRSb7700Ja&default-theme=true

RNS Number : 7700J  Avacta Group PLC  28 October 2024

 

 

 

 

 

 

28 October 2024

 

Avacta Group plc

 

("Avacta" or "the Group" or "the Company")

 

Block Listing Six Monthly Return

 

 

Avacta Group plc (AIM: AVCT), a life sciences company developing next
generation peptide drug conjugates (PDC) targeting powerful anti-tumor
payloads directly to the tumor,  today makes the following notification
pursuant to Schedule Six of the AIM Rules for Companies regarding its existing
block admission arrangements:

 

 Name of applicant:                                                                  Avacta Group plc
 Name of scheme:                                                                     EMI scheme
 Period of return:                         From:                                     28 April 2024          27 October 2024
 Balance of unallotted securities under scheme(s) from previous return:              803,006
 Plus:   The amount by which the block scheme(s) has been increased since            nil
 the date of the last return (if any increase has been applied for):
 Less:   Number of securities issued/allotted under scheme(s) during                 527,626
 period (see LR3.5.7G):
 Equals:   Balance under scheme(s) not yet issued/allotted at end of period:         275,380

 

 Name of applicant:                                                                  Avacta Group plc
 Name of scheme:                                                                     LTIP scheme
 Period of return:                         From:                                     28 April 2024          27 October 2024
 Balance of unallotted securities under scheme(s):                                   9,719,257
 Plus:   The amount by which the block scheme(s) has been increased since            nil
 the date of the last return (if any increase has been applied for):
 Less:   Number of securities issued/allotted under scheme(s) during                 3,806,000
 period (see LR3.5.7G):
 Equals:   Balance under scheme(s) not yet issued/allotted at end of period:         5,913,257

 

 Name of contact:              James Heseltine, Company Secretary
 Telephone number of contact:  + 44 (0) 1904 217070

 

Ends-

 

 

For further information from Avacta Group plc, please contact:

 

 Avacta Group plc

 Michael Vinegrad, Group Communications Director           https://avacta.com/ (https://avacta.com/)
 Peel Hunt (Nomad and Broker)                              www.peelhunt.com (http://www.peelhunt.com/)

 James Steel / Chris Golden / Patrick Birkholm
 ICR Healthcare

                                                           avacta@consilium-comms.com (mailto:avacta@consilium-comms.com)

 Mary-Jane Elliott / Jessica Hodgson / Sukaina Virji

 

About the pre|CISION(®) Platform

The pre|CISION(®) platform comprises an anticancer payload conjugated to a
proprietary peptide that is a highly specific substrate for fibroblast
activation protein (FAP) which is upregulated in most solid tumors compared
with healthy tissues. The pre|CISION(®) platform harnesses this tumor
specific protease to cleave pre|CISION(®) peptide drug conjugates and
pre|CISION(®) antibody/Affimer(®) drug conjugates in the tumor
microenvironment, thus releasing active payload in the tumor and reducing
systemic exposure and toxicity, allowing dosing to be optimized to deliver the
best outcomes for patients.

About AVA6000: FAP-enabled doxorubicin

The lead pre|CISION(®) program AVA6000, a peptide drug conjugate form of
doxorubicin, is in Phase 1 studies. It has shown an improvement in safety and
tolerability in clinical trials to date compared with standard doxorubicin and
preliminary signs of clinical activity in multiple patients.To register for
news alerts by email go
to https://avacta.com/investors/investor-news-email-alerts/
(https://avacta.com/investors/investor-news-email-alerts/) .

AVA6103: FAP-enabled PDC targeting Topoisomerase I

AVA6103 is a pre|CISION-enabled PDC comprised of the pre|CISION peptide linked
to exatecan, the most potent topoisomerase I inhibitor in clinical
development. Exatecan has demonstrated clinical activity in breast, gastric,
lung and pancreatic cancers; however, it is associated with severe
dose-limiting toxicities and a short half-life in patients that led to
discontinuation of its monotherapy development. AVA6103 is designed to enable
patients to obtain the therapeutic benefit associated with exatecan, while
limiting the systemic exposure associated with its poor tolerability.

 

 

AVA7100: pre|CISION(®) FAP Affimer Drug Conjugate (AffDC)

 

AVA7100 is a pre|CISION(®)-enabled Affimer(®) drug conjugate, a new class
of therapies being developed by Avacta with potential applications in a
variety of cancer types, including those with lower levels of FAP in the
tumor. Affimer(® )molecules are small proteins that are engineered to bind
to a target molecule in the same way that an antibody does, but with several
advantages, including smaller molecule size and a broad range of binding
affinity. AVA7100 consists of a novel FAP-Affimer conjugated to a
pre|CISION-peptide linker with multiple options for the payload.

 

About Avacta Group plc - https://avacta.com/ (https://avacta.com/)

Avacta Group is a UK-based life sciences company focused on improving
healthcare outcomes through targeted cancer treatments and diagnostics. Its
clinical stage oncology biotech division Avacta Therapeutics is harnessing the
proprietary pre|CISION(®) platform technology to develop novel, highly
targeted cancer drugs. Avacta Diagnostics focuses on supporting healthcare
professionals and broadening access to diagnostics. To register for news
alerts by email go
to https://avacta.com/investors/investor-news-email-alerts/
(https://avacta.com/investors/investor-news-email-alerts/) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLRPPGPPUUPCGRM